Short Ideas - Optimer Pharmaceuticals (NASDAQ:OPTR) is hosting its Analyst Day in NYC this morning and is detailing its new strategy, which includes lowering the price for lead … Continue Reading
Read nowLong Ideas - By now, the bear story on Questcor Pharmaceuticals (NASDAQ:QCOR) is well understood, with health insurer Aetna (NYSE:AET) indicating that it will make it next-to-impossible to … Continue Reading
Read nowQuick Picks - Early Monday, Cell Therapeutics (NASDAQ:CTIC) announced that its JAK2 inhibitor pacritinib demonstrated good tolerability and evidence of cancer-fighting behavior in a 34 patient Phase I … Continue Reading
Read nowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read nowQuick Picks - On Wednesday morning, Opexa Therapeutics (NASDAQ:OPXA) announced the initiation of a Phase IIb trial, called Alibi-T, for Tcelna, the company’s T-cell therapy for multiple sclerosis. … Continue Reading
Read now- The Debiopharm Group and Curis, Inc (NASDAQ:CRIS) announced this morning the beginning of a Phase I/II clinical study of Debiopharm’s development-stage Debio 0932, a second-generation … Continue Reading
Read nowResearch - Short interest in ResMed Inc. (NYSE:RMD) is at its highest point this year, signaling that investors are growing increasingly bearish on the company’s valuation and … Continue Reading
Read now